Publicaciones en colaboración con investigadores/as de Memorial Sloan Kettering Cancer Center (103)

2024

  1. Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX

    Blood Advances, Vol. 8, Núm. 2, pp. 388-398

2023

  1. A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 4, pp. 711-722

  2. Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, Núm. 5, pp. 385-393

  3. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

    Blood

  4. Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study

    Leukemia and Lymphoma

  5. Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study

    Blood Advances, Vol. 7, Núm. 14, pp. 3739-3748

  6. Global disparities in patients with multiple myeloma: a rapid evidence assessment

    Blood Cancer Journal, Vol. 13, Núm. 1

  7. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel

    Blood cancer journal, Vol. 13, Núm. 1, pp. 116

  8. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2

    British Journal of Cancer, Vol. 128, Núm. 12, pp. 2283-2294

  9. Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma

    Blood Advances, Vol. 7, Núm. 22, pp. 7141-7150

  10. Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia

    Future Oncology, Vol. 19, Núm. 5, pp. 345-353

  11. Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 19, Núm. 12, pp. 811-818

  12. Profiling the immune landscape in mucinous ovarian carcinoma

    Gynecologic Oncology, Vol. 168, pp. 23-31

  13. Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients

    Seminars in Hematology

  14. Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials

    Seminars in Hematology

  15. Sawubona reprise: reflections on the European Society of Thoracic Surgeons Presidential Address 2022

    Journal of Thoracic Disease

2022

  1. Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma

    Haematologica, Vol. 107, Núm. 10, pp. 2408-2417

  2. Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment

    Frontiers in Oncology, Vol. 12

  3. Guiding the global evolution of cytogenetic testing for hematologic malignancies

    Blood, Vol. 139, Núm. 15, pp. 2273-2284

  4. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 1, pp. 52-62